A comprehensive view of liver/kidney/bladder health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Regeneron and partner Alnylam Pharmaceuticals to move into Phase 2 trials with their experimental injectable liver disease drug ALN-HSD to treat nonalcoholic steatohepatitis after encouraging Phase 1 findings
Published: September 16, 2022 by SeeNews Pharmaceuticals
Bayer updates label of kidney drug Kerendia finerenone in US to indicate the medicine cuts cardiovascular event risk in patients with chronic kidney disease and type 2 diabetes; Bayer expects Kerendia and heart medicine Verquvo to drive long-term growth
Published: September 06, 2022 by SeeNews Pharmaceuticals
Korea's Chung-Ang University investigates effects of combined BPA and phthalates exposure on liver function, metabolism in animal study; neither chemical affects liver function at permissible levels, but show significant impact when combined, study finds
Published: August 05, 2022 by PR Newswire
Roche receives global license to advance Ionis Pharmaceuticals’ injectable IONIS-FB-LRX to treat kidney disease for US$55M; drug based on Ionis’ antisense technology, has potential to treat other inflammatory conditions
Published: July 13, 2022 by SeeNews Pharmaceuticals
FDA places partial hold on late-stage study of Sanofi’s tolebrutinib to treat patients with multiple sclerosis, myasthenia gravis; FDA cites limited number of cases of drug-induced liver injury as cause for hold
Published: July 05, 2022 by SeeNews Pharmaceuticals

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count